bioRxivNeurosciencePreprint
Mitochondrial Carbonic Anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models
Nicole L LemoniD, Elisa CanepaiD, Rafael Vázquez‐Torres, Rebecca Maria Parodi‐RullániD, Tina HirtiD, Lisa M. PetersohniD, Tashnuva RifatiD, Maryam H. AbyanehiD, Marc Antoniu IliesiD, Silvia FossatiiD
Abstract
Alzheimers Disease (AD) is a devastating neurodegenerative disorder with no effective cure, characterized by the cerebral parenchymal and vascular accumulation of aggregated Amyloid-{beta} (A{beta}) and hyperphosphorylated tau. Cerebrovascular and mitochondria dysfunction are early causal events in the progression of AD. Previous studies support that inhibiting carbonic anhydrases (CA) may prevent mitochondrial and cerebrovascular dysfunction in AD models. Here, we selectively target the mitochondrial CA isoform CA-VB by pharmacological and genetic manipulation, in human cerebral microvascular endothelial cells (hCMEC) and we confirm the protective effects of the CA-V inhibitor in AD mice. CA-V inhibition and CA-VB KO prevent A{beta} induced mitochondria-mediated endothelial apoptosis, loss of barrier resistance, and hCMEC inflammatory activation. Strikingly, CA-V inhibition also mitigates caspase activation and endothelial cell activation in the brains of 3xTg AD mice, resulting in preserved memory function. Our results demonstrate that selective CA-V inhibition is an effective and promising strategy against AD-mediated cerebrovascular pathology, neuroinflammation and cognitive impairment.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- FDA-approved carbonic anhydrase inhibitors reduce Amyloid beta pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness
Elisa Canepa, Rebecca Maria Parodi‐Rullán, … Silvia Fossati·Alzheimer s & DementiaPeer-reviewed·Apr 26, 2023
- mTOR drives cerebrovascular dysfunction and blood-brain barrier breakdown in a model of Alzheimers disease with cerebral amyloid angiopathy
Candice E. Van Skike, Lauren R. Miller, … Verónica Galván·bioRxiv·Sep 7, 2026
- Carbonic anhydrase inhibition rescues heart function in the Tg2576 Alzheimer's mouse model by ameliorating cardiac amyloid-β pathology and neurotrophic signaling impairment.
Andrea Elia, Rafael Vázquez‐Torres, … Silvia Fossati·bioRxiv·Oct 9, 2026
- Carbonic anhydrase inhibitors prevent presymptomatic capillary flow disturbances in a model of cerebral amyloidosis
Eugenio Gutiérrez‐Jiménez, Peter Mondrup Rasmussen, … Leif Østergaard·Alzheimer s & DementiaPeer-reviewed·Mar 1, 2025
- Genetic ablation of neuronal mitochondrial calcium uptake halts Alzheimer's disease progression
Pooja Jadiya, E.V. Berezhnaya, … John W. Elrod·The EMBO JournalPeer-reviewed·May 22, 2026
- Molecular Mechanisms Underlying the Regulation of VCAM-1 Expression by the Short-Chain Fatty Acid Butyrate
Vrishali S. Salian, Vaishnavi Veerareddy, … Karunya K. Kandimalla·bioRxiv·Dec 17, 2025